Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the United States Food and Drug Administration (USFDA).
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD); and to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD. Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of $446 million in the U.S. (IQVIA MAT January 2025).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
